Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $45.00 at Wells Fargo & Company

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lowered by Wells Fargo & Company from $65.00 to $45.00 in a report issued on Tuesday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on RARE. TD Cowen cut their target price on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Truist Financial cut their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $75.19.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $22.78 on Tuesday. The company has a market cap of $2.20 billion, a P/E ratio of -3.84 and a beta of 0.16. The firm’s fifty day moving average price is $33.43 and its two-hundred day moving average price is $32.01. Ultragenyx Pharmaceutical has a one year low of $18.41 and a one year high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm had revenue of $159.93 million for the quarter, compared to the consensus estimate of $167.42 million. During the same quarter last year, the business posted ($1.40) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 14.6% on a year-over-year basis. As a group, equities research analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Activity

In other news, CFO Howard Horn sold 3,081 shares of the company’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the sale, the chief financial officer directly owned 95,146 shares in the company, valued at $3,461,411.48. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders sold 11,108 shares of company stock worth $365,262. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares during the period. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical in the second quarter worth $35,765,000. Adage Capital Partners GP L.L.C. grew its stake in Ultragenyx Pharmaceutical by 81.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock worth $77,815,000 after purchasing an additional 965,919 shares during the period. Assenagon Asset Management S.A. lifted its position in Ultragenyx Pharmaceutical by 439.0% during the second quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company’s stock valued at $42,314,000 after buying an additional 947,865 shares during the period. Finally, Vestal Point Capital LP purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $22,560,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx completed the rolling BLA submission to the FDA for DTX401 (pariglasgene brecaparvovec) for GSDIa — the filing now includes CMC, clinical and non‑clinical modules; the program has RMAT/ Fast Track/orphan designations and Phase 3 data across ~52 patients showing reduced cornstarch use and improved glycemic control. This is a multi‑year commercial catalyst if approved and would be the first therapy addressing the underlying cause of GSDIa. GlobeNewswire: BLA Submission
• Positive Sentiment: Unusual options activity: an above‑average number of call contracts traded, indicating speculative/hedged bullish interest that may amplify intraday upside.
• Neutral Sentiment: Analysts revised price targets lower after the recent volatility but largely maintained Outperform/Buy ratings (examples: Baird, Leerink, Jefferies, Wells Fargo), leaving materially higher median targets than the current price — reflects confidence in longer‑term pipeline value but acknowledges near‑term uncertainty. Benzinga: Analyst Moves
• Neutral Sentiment: Small insider sale disclosed (CAO sold 85 shares) — immaterial to ownership but noted by market participants. SEC filing: SEC Filing
• Negative Sentiment: Major negative catalyst: Ultragenyx and partner Mereo announced that two Phase 3 studies of setrusumab in osteogenesis imperfecta failed to meet primary endpoints (no reduction in fracture rate), which precipitated a steep market decline and prompted operational retrenchment announcements. This materially reduces near‑term revenue prospects and created significant investor uncertainty. Reuters: Setrusumab Phase 3 Failure
• Negative Sentiment: Two law firms (Pomerantz, Portnoy) announced investigations into Ultragenyx that may lead to securities litigation related to the trial misses and disclosures — potential legal overhang and expense risk. GlobeNewswire: Pomerantz GlobeNewswire: Portnoy
• Negative Sentiment: Market mechanics: trading was halted as key news hit and the shares experienced extreme intraday volatility and high volume, reflecting rapid re‑pricing and elevated risk for short‑term holders. Coverage and headlines amplified the selloff. MarketWatch: Shares Slide

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.